Business Context and Reporting Period
This Form 8-K is a current report filed by Collegium Pharmaceutical, Inc. on September 29, 2020, regarding events occurring on September 30, 2020. The filing addresses the resolution of patent litigation concerning the Company's product, Xtampza ER.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a legal settlement and does not contain financial statement data.
Material Changes and Events
The primary material event is the entry into a definitive settlement agreement with Teva Pharmaceuticals USA, Inc. ("Teva") regarding patent litigation in the U.S. District Court for the District of Delaware. Key terms include:
- License Grant: Collegium will grant Teva a license to market a generic version of Xtampza ER in the United States beginning on or after September 2, 2033.
- Conditions: The launch date is subject to U.S. Food and Drug Administration approval and potential acceleration under certain circumstances.
- Consent Judgment: Teva has agreed to a consent judgment confirming that its proposed generic products infringe upon Collegium's asserted patents and that those patents are valid and enforceable.
- Regulatory Review: The settlement is subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Guidance, Outlook, and Risks
The filing does not provide updated financial guidance or management commentary on future financial performance. The primary risk noted is the regulatory review of the settlement by federal agencies. Additional details regarding the settlement are confidential and redacted in the filed exhibits.
Investor Verification Checklist
- Verify the final approval status of the settlement by the FTC and DOJ.
- Review the redacted Exhibit 10.1 (Settlement Agreement) for any undisclosed financial terms or acceleration clauses.
- Monitor FDA approval timelines for Teva's generic version of Xtampza ER.
- Assess the impact of the 2033 launch date on the projected revenue lifecycle of Xtampza ER.